Background The effects of fourth-generation drospirenonecontaining combined oral contraceptives (COCs) on the risk of venous thromboembolism (VTE) are controversial.
Introduction
Oral contraceptives (OCs) are commonly prescribed to prevent unwanted pregnancies. 1 Estimates suggest that approximately 17.1% of women aged 15-44 years in the USA are currently using OCs. 2 Combined oral contraceptives (COCs) were first introduced in the 1960s, and include both an estrogen and a progestin component. An increased risk of venous thromboembolism (VTE) has been associated with their use, 3, 4 but whether this risk is higher for more recent generations of COCs is controversial. This controversy stems, in part, from several observational studies published in the 1990s that suggested third-generation COCs were associated with an increased risk of VTE compared with second-generation COCs, resulting in the 'pill scare'. [5] [6] [7] [8] It was subsequently shown, however, that this apparent increased risk was largely the result of important limitations in the design and analysis of several of these studies. 9 The fourth generation of COCs contains the progestin drospirenone, and was introduced to the market in 2000.
Although controversial, some evidence suggests that newer COCs improve acne and hirsutism compared with some older contraceptives. In addition, there is some evidence that 3 mg of drospirenone plus 20 micrograms of ethinyloestradiol may improve severe premenstrual symptoms. 10 Several observational studies have since assessed the VTE risk of drospirenone-containing COCs, with these studies producing heterogeneous results, as shown in previous systematic reviews and meta-analyses of this issue. [11] [12] [13] [14] None of these previous reviews have adequately assessed the methodological strengths and limitations of the observational studies when synthesising these data, however, or their role in explaining the existing heterogeneity. We therefore conducted a systematic review of observational studies examining the VTE risk of drospirenone-containing COCs, with a focus on the methodological strengths and limitations of the individual studies assessing this association.
Methods
Our systematic review was conducted following a pre-specified protocol, and is reported following the guidelines described in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 15 
Search strategy
We systematically searched CINAHL, Cochrane Library Online, EMBASE, Healthstar, Medline, and the Science Citation Index from inception to November 2015 to identify all studies examining the association between drospirenone-containing COCs and VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE). We also hand-searched the grey literature and the references of relevant articles, previous reviews, and meta-analyses on this topic. Our search strategy is reported in detail in Table S1 . Briefly, we used Medical Subject Heading terms for Medline, EMTREE terms for Embase, and keywords for all databases for drospirenone, and all generic and trade names for drospirenone-containing COCs. The search was conducted with no restrictions on study design or language of publication.
Inclusion and exclusion criteria
Studies were included if they: (1) were comparative studies (cohort studies, case-control studies, and their derivatives) of women taking drospirenone-containing COCs; (2) reported at least one venous thrombotic outcome (VTE, DVT, or PE); (3) had at least one comparator group; (4) reported at least one effect measure of the association of interest (odds ratio, OR; hazards ratio, HR; incidence rate ratio, IRR; risk ratio, RR) or sufficient data for its calculation; and (5) were published in English or French. Crosssectional studies, reviews, editorials, commentaries, conferences abstracts, and randomised controlled trials were excluded.
Title and abstract screening was performed independently by two reviewers (NL and FKK), with any article deemed potentially relevant by either reviewer carried forward for full-text review. The full texts of potentially relevant articles were reviewed by both reviewers, with any disagreements resolved by consensus or by a third reviewer (KBF).
Data extraction
Data were independently extracted by two reviewers (NL and FKK), with disagreements resolved by consensus or by a third reviewer (KBF). The following information was extracted: study characteristics (study design, sample size for both drospirenone-containing COCs and comparator, data source, study period, patient population), VTE incidence rates (IRs) with 95% confidence intervals (95% CIs) overall, and by exposure group, effect measures (OR, HR, IRR, and RR) with 95% CIs, and approaches used to control for confounding (matching variables, exclusion criteria, and confounding factors included in statistical models).
The results of analyses comparing drospirenone-containing COCs with the following comparator groups were extracted: levonorgestrel-containing COCs (main comparator of interest), other COCs (first-generation norethindrone acetate, second-generation levonorgestrel and norethisterone, and third-generation gestodene and norgestimate), and non-use of OCs (defined as a woman who was not using any form of oral contraceptive). We did not report comparisons made versus third-generation COCs as they are infrequently used because of the pill scare. Heterogeneity was assessed qualitatively; no formal tests of heterogeneity were performed as we conducted a systematic review without meta-analysis.
Quality assessment
Overall, study quality was assessed using the Risk Of Bias in Non-randomised Studies -of Interventions (ROBINS-I). 16 Seven domains were assessed based on signalling questions tailored to either cohort or case-control study designs: bias because of confounding; bias in the selection of participants for the study; bias in the classification of interventions; bias because of the departure from intended interventions; bias because of missing data; bias in the measurement of outcomes; and bias in the selection of the reported results. Based on the assessment of each domain, an overall risk of bias was assigned as low, moderate, serious, or critical, with the minimum overall risk typically determined by the highest risk assigned in any individual domain. Given the potential for confounding, the highest quality studies will be those with a moderate risk of bias overall. Given concerns regarding the potential presence of prevalent user bias, inappropriate choice of comparator, VTE misclassification, and confounding, we also specifically assessed the presence of these biases by describing, for example, whether or not the study included prevalent users. Using the ROBINS-I assessment and the evaluation of the four individual biases, we then considered studies to be of high quality if the ROBINS-I yielded a low or moderate risk and none of the four individual biases were present.
Prevalent user bias
Prevalent user bias occurs when the history of use of the exposure (i.e. drospirenone-containing COCs) and/or its comparator is not adequately considered when identifying the study cohort or analysing the data. A COC user may be classified as any of the following four user types: a first-ever user (a woman who has never used drospirenonecontaining COCs or their comparator before); a new user (either a first-ever user or a woman who is restarting use after a given period of non-use, often 6 months or 1 year); a switcher (a woman who is switching from one COC to another at the time of cohort entry); or a prevalent user (a woman who was already for some time using the COC that resulted in cohort entry). The risk of thrombosis is greatest among first-ever users and during the first year of COC use, and subsequently decreases. 9, 17 Differences in the distribution of user types (and corresponding VTE risk) across exposure groups can therefore result in important bias, particularly when comparing different generations of COCs. Differences in the history of COC use led to spurious associations between third-generation COCs and VTE. 9 Given the differential timing of the entry of COCs into the market, participants taking third-generation COCs typically had a shorter duration of use than those taking second-generation COCs, and were more likely to be first-ever users ( Figure S1 ). In contrast, second-generation users were more likely to include women who were restarting COCs and prevalent users, and thus had necessarily survived the 'high-risk' first year; women in this group who experienced a VTE during the high-risk period did so before cohort entry, and were thus excluded because of their history of VTE. This resulted in a depletion of susceptibles among second-generation COC users, and consequently a spurious increased risk among third-generation users (Figure 1 ). When analyses controlled for the differential duration of use, the apparent increased risk disappeared. 9 In addition, restarting after a period of non-use and, to a lesser degree, switching COCs also increase the risk of VTE, although these increased risks do not reach that observed among first-time users.
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Inappropriate choice of comparator All COCs are associated with an increased risk of thrombosis, relative to the non-use of COCs, as a result of haemostatic changes associated with their use. 3, 4 The use of an inactive comparator is therefore expected to result in an observed increased risk. Although a comparison of the VTE risk of drospirenone-containing COCs with that of the non-use of OCs is a valid comparison, it does not address the clinically relevant question that is the object of controversy, namely 'Is the VTE risk of drospirenone-containing COCs greater than that of other commonly-prescribed COCs?' Although it could be argued that a comparator group of non-use is an issue of external validity (i.e. generalisability), and not internal validity, and that such studies represent a different 'ideal' trial that is being mimicked in an observational setting, these studies are typically included when discussing the VTE risk of drospirenone-containing COCs, and have thus been included in the present review.
Misclassification of VTE
A common source of bias in studies examining the VTE risk of COCs is the misclassification of VTE status. In our assessment, we considered the authors' VTE definition as well as any included validation processes, and assigned a risk of VTE misclassification of low, moderate, or high. Low risk was given to studies where the event definition was based on objective, radiological measures, to studies using a database for which VTE had been previously validated, and to studies in which the authors validated events. For example, studies that were restricted to 'confirmed' events in which the VTE diagnosis was accompanied by a prescription for an anticoagulant were considered low risk. Moderate risk was assigned to studies with no requirement for anticoagulant therapy prescriptions to supplement diagnoses or to those that did not consider outpatient events. Restriction to hospitalisation codes results in the exclusion of VTEs treated in an outpatient setting, which may result in bias if differential between exposure groups. Serious risk was assigned to studies with both no requirement for anticoagulant therapy prescriptions to supplement diagnoses and no discussion of the validity of the data. Critical risk was assigned to studies using self-administered questionnaires and to those in which events were restricted to nonhospitalised VTEs (and thus excluded all inpatient events).
Confounding
Confounding can occur in three ways: (1) as a result of known confounding factors that were not adequately considered in the design or analysis of a study, typically because they were poorly measured or not available; (2) as a result of unknown confounding factors; or (3) as a result of time-varying changes to confounder levels during follow-up. The first scenario is the most relevant to this review. Known confounding factors of the COC-VTE association include age, obesity, or body mass index, previous history of thrombosis, and family history of thrombosis. Failure to account for these variables, either through study design (i.e. restriction, matching) or analytical approaches (i.e. stratification, regression analyses), may result in bias. Moreover, all of the included studies are observational in nature and thus susceptible to residual confounding by unknown variables.
Results

Literature search
Our search identified 4625 potentially relevant publications ( Figure S2 ). After the removal of duplicates and the addition of two publications identified in the grey literature, 2524 publications underwent title and abstract review. The full texts of 20 studies were assessed, 17 of which were included in our systematic review (11 cohort [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] and six case-control [30] [31] [32] [33] [34] [35] ).
Study and patient characteristics
The 17 studies examining the VTE risk of drospirenone-containing COCs included 2 246 361 women (cohort studies, 2 239 339 women; case-control studies, 2230 cases and 4792 controls; Tables 1 and S2 ). Although drospirenone-containing COCs only became available in 2000, the study periods ranged from 1995 to 2013: studies that included periods before the year 2000 examined the risk of VTE from other OCs initially, and included drospirenone-containing COCs as a secondary exposure category when data became available. The studies included data from the USA, UK, Israel, Germany, and Denmark. Study populations were heterogeneous, with some studies including all women and others having several exclusion criteria, such as previous thrombotic events, serious illness, cancer, cardiovascular disease, risk factors for VTE, and gynaecological surgeries.
Drospirenone-containing COCs and the risk of VTE
Eight studies compared the risk of VTE for multiple groups of OC users, 19, 20, 26, 27, 29, 31, 32, 34 whereas the remaining nine studies made only one comparison. Fifteen studies compared the risk of VTE between users of drospirenone-and levonorgestrel-containing COCs ( Figure 1 ; Table 2 ). [19] [20] [21] [23] [24] [25] [26] [27] [29] [30] [31] [32] [33] [34] [35] One study used an approach analogous to 'intention to treat', and 14 used a time-dependent exposure definition. The IR ranged from 2.3 to 13.7 VTEs per 10 000 woman-years among drospirenone-containing COC users, and from 0.7 to 9.8 VTEs per 10 000 woman-years among levonorgestrel-containing COC users. The RR for VTE associated with drospirenone-versus levonorgestrel-containing COCs ranged from 1.0 to 2.4, with the exception of one study, which reported an OR of 3.3.
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Six studies compared the risk of VTE between users of drospirenone-containing COCs and users of other COCs ( Figure S3 ; Table 2) . 19, 20, 22, 26, 28, 29 The IRs ranged from 4.4 to 13.0 VTEs per 10 000 woman-years among drospirenone-containing COC users, and from 0.7 to 14.0 VTEs per 10 000 woman-years among other COC users. The RRs ranged from 0.8 to 1.3, with the exception of one study, which reported an RR of 6.4.
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Five studies compared the risk of VTE between users of drospirenone-containing COCs and non-users of OCs (Figure S4 ; Table 2) . 23, 27, 31, 32, 34 The IRs ranged from 7.8 to 13.7 VTEs per 10 000 woman-years among drospirenonecontaining COC users, and from 3.0 to 8.2 VTEs per 10 000 woman-years among non-users. The relative risks ranged from 1.8 to 8.4.
It should be noted that several studies included additional analyses restricting to 'confirmed' versus 'not confirmed' VTE cases, 20 micrograms or 30-40 microgram estrogen pills, and 21-day or 24-day pills. 20, 24, 25, 27, 29, 32 These analyses were considered in our bias assessments, but the results of these additional analyses were not considered.
Overall quality assessment
Based on ROBINS-I, three studies were assigned a moderate risk of bias, 21, 24, 35 ten studies were assigned a serious risk of bias, 19, 20, 22, [25] [26] [27] 29, [32] [33] [34] and four studies were assigned a critical risk of bias (Table 3) . 23, 28, 30, 31 The two domains that led to the greatest increase in the risk of bias were 'risk of bias as a result of confounding' and 'risk of bias in measurement of outcomes' (Table S3) . For bias as a result of confounding, one study had a low risk, 35 six studies had a moderate risk, [20] [21] [22] 24, 26, 34 six studies had a serious risk, 19, 25, 27, 29, 32, 33 and four studies had a critical risk. 23, 28, 30, 31 For bias in outcome measurement, two studies had a low risk, 22, 32 nine studies had a moderate risk, 19, 20, 23, 25, 26, 29, 31, 34, 35 five studies had a serious risk, 21, 24, 30, 33 and one study had a critical risk.
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In-depth assessment of COC-VTE specific biases
The results of the in-depth assessment of four biases specific to the study of the COC-VTE association are summarised in Table 3 .
Prevalent user bias
Eight studies were restricted to new users only, and were thus less likely to have prevalent user bias (Table S4) . 19, 22, [24] [25] [26] 29, 30, 33 Given the left censoring of many databases and the corresponding challenges in identifying first-time use, however, the presence of prevalent user bias cannot be completely ruled out in many of these studies. In addition, nine studies included all user types (first time users, new users, switchers, and prevalent users), 20, 21, 23, 27, 28, 31, 32, 34, 35 and were thus likely to be affected by prevalent user bias. None of these studies accounted for previous COC use in their primary analysis, although many acknowledged the importance of doing so.
Inappropriate choice of comparators
Five of 17 studies included comparisons with the non-use of OCs, 23, 27, 31, 32, 34 with four considering this as their primary analysis. 23, 27, 31, 32 Given the known VTE risk associated with the use of any COC, the use of such inactive comparators is not clinically relevant.
Misclassification of VTE
Venous thromboembolism (VTE) can be difficult to define, particularly when using administrative data. Consequently, without the use of a validated outcome definition, the misclassification of VTE status can occur. Six studies had a low risk of bias for VTE misclassification, 24, [29] [30] [31] [32] 35 seven studies had a moderate risk, 19, 20, 22, 26, 27, 33, 34 and four studies had a serious or critical risk (Table S5) . 21, 23, 25, 28 The four studies with the highest risk provided no information regarding their VTE definition and its validity.
Confounding
All of the included studies were observational, and thus were likely to be affected by residual confounding as a result of unknown confounding factors. Five studies did Comparator is second-generation COCs, which includes the combination of norgestrel and levonorgestrel. # Includes 28 VTE cases exposed to drospirenone, 72 controls exposed to drospirenone, 121 VTE cases unexposed to drospirenone, 313 controls unexposed to drospirenone. **Estimate reported for drospirenone 30-40 micrograms of EE and confirmed VTE events. Study also includes drospirenone versus levonorgestrel, with adjustment for length of use (RR 2.09; 95% CI 1.55-2.82), estimates for drospirenone 20 micrograms of EE (RR 2.22; 95% CI 1.27-3.89) and by certainty of diagnosis. † † The IRR presented is for confirmed VTE cases; among non-confirmed VTEs, the IRR is 1.78 (95% CI 1.21-2.60). ‡ ‡ The OR is based on 17 VTE cases exposed to drospirenone, 26 controls exposed to drospirenone, 61 VTE cases unexposed to drospirenone, and 189 controls unexposed to drospirenone.
§ § OR is presented for multiple imputation analysis. |||| OR is based on 55 VTE cases exposed to drospirenone, 11 controls exposed to drospirenone, 498 VTE cases unexposed to drospirenone, 620 controls unexposed to drospirenone. ¶ ¶ Estimate is shown for drospirenone 24-d regimen. OR is based on 19 VTE cases exposed to drospirenone, 14 controls exposed to drospirenone, 421 VTE cases unexposed to OCs, and 1102 controls unexposed to OCs. § § § RR is presented for drospirenone 30-40 micrograms of EE and confirmed VTE events; for 20 micrograms of EE, the RR is 6.95 (95% CI 4.21-11.5).
not account for or consider two or more known confounding factors, [22] [23] [24] 27, 28 typically because these confounding factors were not recorded in the study data source (Table S6) . One study included used a clinically-derived propensity score to reduce residual confounding. 22 Finally, none of the included studies attempted to adjust for timevarying confounding (i.e. changes in confounding factors during follow-up) through the use of techniques such as marginal structural models.
Discussion
Main findings
Our study was designed to synthesise the available literature regarding the VTE risk of drospirenone-containing COCs, with a focus on the methodological strengths and limitations of this literature. We identified 17 studies that met our inclusion criteria. We found that all studies comparing drospirenone users with levonorgestrel users suggested some degree of increased VTE risk with drospirenone-containing COCs, with RRs ranging from 1.0 to 3.3. The body of literature examining the VTE effects of drospirenone-containing COCs has several limitations, however. Using ROBINS-I to assess the overall study quality, we found that three studies were assigned a moderate risk of bias, 21, 24, 35 ten studies were assigned a serious risk of bias, 19, 20, 22, [25] [26] [27] 29, [32] [33] [34] and four studies were assigned a critical risk of bias. 23, 28, 30, 31 Furthermore, our assessment of four specific sources of bias revealed that these biases were prevalent in this literature. Nine studies had prevalent user bias, four studies included inappropriate comparators, four studies had VTE misclassification, and five studies had important residual confounding. The IRs for VTE in studies with a low or moderate risk of misclassification ranged from 4.0 to 10.2 among drospirenone users and 3.0 to 6.6 among the users of comparators. Studies with the highest quality suggest that drospirenone-containing COCs are either not associated with or slightly increase the risk of VTE, relative to levonorgestrel-containing COCs. 21, 24, 35 
Strengths and limitations
Our study has many strengths. First, the study followed a pre-specified protocol. Second, our comprehensive systematic search included six databases. Third, our study included the use of the Cochrane Collaboration's ROBINS-I tool to assess the overall study quality. We also considered four potential sources of bias related to the study of COCs and VTE. Finally, to our knowledge, this is the first systematic review to focus on the methodological strengths and limitations of the studies examining this relationship.
Our study also has some limitations. First, we did not include comparisons with third-generation COCs given the controversy surrounding them and the presence of bias in some of these studies. 9 Although third-generation COCs were included in comparisons, we excluded comparisons in studies that focused entirely on third-generation COCs. We acknowledge that there may be a small number of studies that were excluded from this assessment. Second, given the presence of several potential limitations in the included studies and the modest quality of this literature, there were few high-quality studies on which to base substantive conclusions. Third, as is true for all systematic reviews, there is the potential for publication bias. Fourth, with the presence of heterogeneity in study design, study definitions, and study populations, as well as the presence of several limitations in this literature, we were unable to pool results across studies. We believe, however, that a thorough and systematic methodological assessment of this literature is needed to better understand the safety of drospirenone-containing COCs.
Interpretation (in light of other evidence)
The VTE risk of drospirenone-containing COCs has been the focus of several regulatory reviews. Following the completion of a 2011 US Food and Drug Association (FDA) funded study using the Kaiser Permanente and Medicaid databases, the FDA determined that drospirenone-containing COCs may increase the risk of VTE relative to other COCs. 24 The FDA subsequently revised the product labelling to indicate that some epidemiological studies reported increased risks as high as threefold, whereas others found no additional risk. 36 In addition, a 2013 European Medicines Agency review concluded that the benefits of all COCs (including drospirenone-containing COCs), such as preventing unwanted pregnancy, continue to outweigh the minimal risk of VTE. 37 In contrast, Health Canada concluded that drospirenone-containing COCs may be associated with a relative risk of VTE of 1.5-3.0, compared with other COCs. 38 An important aspect of this work is to provide an additional tool to allow doctors and women seeking birth control the information required for informed decisionmaking regarding the benefits, risks, and uncertainty of drospirenone-containing COCs. The identified limitations of the existing literature have important implications for knowledge users, including regulatory agencies, healthcare professionals, and patients. The consequences of methodological shortcomings in this area were well illustrated in the 'pill scare' of the 1990s, 9 where as a result of methodologically flawed studies, women began to discontinue their use of third-generation COCs, resulting in many unwanted pregnancies and terminations of pregnancy. 5 Given the number of women exposed to drospirenone-containing COCs and the clinical consequences of VTE, there remains a need for additional, methodologically rigorous studies to determine the VTE risk of drospirenone-containing COCs relative to other COCs.
A more methodologically robust design would be a cohort study restricted to first-time users in which women are followed until VTE, or censoring for discontinuation of use, switching to a different hormonal contraceptive, death, departure from the database, or end of the study period. By restricting recruitment to first-time users only, the study would ensure that women are compared at a similar point on the COC-VTE risk curve, and avoid the potential effects of prevalent user bias. In addition, this approach would avoid any dilution of effects typically seen in intention-totreat analyses. Given the known early risk of VTE with firsttime use of COCs, studies with long follow-up may dilute the risk if hazards are, as expected, non-proportional. Moreover, it has been shown that COC users who interrupt or switch COC use have a different VTE risk profile than continuous COC users, 9 ,17 making it difficult to interpret timedependent or nested case-control analyses of this relationship. The reference category for such an analysis would be use of levonorgestrel-containing COCs, a clinically relevant comparator and the most commonly used COC in the UK. 31, 39 To avoid the misclassification of VTE, the outcome should be defined by an inpatient diagnosis or an outpatient diagnosis of VTE, accompanied by a prescription for anticoagulant therapy, international normalised ratio (INR) testing (indicative of monitoring anticoagulation), or death shortly after the event. 40, 41 Finally, to minimise residual confounding, the use of approaches such as high-dimensional propensity scores should be considered.
Conclusion
Although several observational studies have examined the association between drospirenone-containing COCs and the risk of VTE, the methodological limitations of this literature render it difficult to interpret. Indeed, many of these studies had conclusion-altering biases, such as prevalent user bias, which was present in nine of the 17 included studies. The highest quality studies of this association suggest no or slightly increased harmful effects, but their confidence limits do not rule out an almost doubling of the risk. Large, methodologically rigorous studies are needed to provide an accurate safety profile of these COCs.
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